Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate
01 Février 2024 - 5:45PM
Business Wire
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor
of Cellvizio®, the multidisciplinary probe and needle-based
confocal laser endomicroscopy (p/nCLE) platform, today announces
initiation of coverage by EuroLand Corporate.
In a study entitled "L’imagerie cellulaire à la loupe", EuroLand
Corporate recommends Mauna Kea shares to Buy, with a target price
of €0.71, representing an increase of +56% compared with the
share's closing price on January 31, 2024 (€0.456).
This new study adds to the consensus of financial analysts who
already covers the stock alongside Portzamparc and Gilbert
Dupont.
***
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that
manufactures and sells Cellvizio®, the real-time in vivo cellular
imaging platform. This technology uniquely delivers in vivo
cellular visualization which enables physicians to monitor the
progression of disease over time, assess point-in-time reactions as
they happen in real time, classify indeterminate areas of concern,
and guide surgical interventions. The Cellvizio® platform is used
globally across a wide range of medical specialties and is making a
transformative change in the way physicians diagnose and treat
patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about
Mauna Kea Technologies and its business. All statements other than
statements of historical fact included in this press release,
including, but not limited to, statements regarding Mauna Kea
Techonologies' financial condition, business, strategies, plans and
objectives for future operations are forward-looking statements.
Mauna Kea Technologies believes that these forward-looking
statements are based on reasonable assumptions. However, no
assurance can be given that the expectations expressed in these
forward-looking statements will be achieved. These forward-looking
statements are subject to numerous risks and uncertainties,
including those described in Chapter 3 of Mauna Kea Technologies'
2022 Universal Registration Document filed with the Autorité des
marchés financiers (AMF) on June 28, 2023 under number D-23-0545,
which is available on the Company's website (www.maunakeatech.fr),
as well as the risks associated with changes in economic
conditions, financial markets and the markets in which Mauna Kea
Technologies operates. The forward-looking statements contained in
this press release are also subject to risks that are unknown to
Mauna Kea Technologies or that Mauna Kea Technologies does not
currently consider material. The occurrence of some or all of these
risks could cause the actual results, financial condition,
performance or achievements of Mauna Kea Technologies to differ
materially from those expressed in the forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or subscribe for, or the solicitation
of an order to buy or subscribe for, shares of Mauna Kea
Technologies in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. The
distribution of this press release may be restricted in certain
jurisdictions by local law. Persons into whose possession this
document comes are required to comply with all local regulations
applicable to this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240201964485/en/
Mauna Kea Technologies - Investor Relations investors@maunakeatech.com
NewCap - Investor Relations Aurélie Manavarere / Thomas
Grojean +33 (0)1 44 71 94 94 maunakea@newcap.eu
Mauna Kea Technologies (EU:ALMKT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Mauna Kea Technologies (EU:ALMKT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024